ClarivateTM Analytics released the 2021 update of its Journal Citation Reports©, including the much anticipated 2020 impact factor. EASL’s flagship monthly journal, the Journal of Hepatology, achieved unprecedented results with a 2020 impact factor of 25.083, up from the 2019 score of 20.582. Gen…
For Immediate Release Media Release Treatment advances for Non-Alcoholic Fatty Liver Disease (NAFLD) announced at ILC 2021 New data released on trials involving RNAi therapeutics, antivirals and structurally engineered fatty acids to treat NAFLD Friday 25 June 2021 (Geneva, Switzerland)– Leading …
For Immediate Release Media Release Advances in new drugs to for curing Hepatitis B and Hepatitis D announced at ILC 2021 Thursday 24 June 2021 (Geneva, Switzerland)– Leading hepatology researchers announced important new developments in hepatitis research at the International Liver Congress 2021…
For Immediate Release Media Release ILC 2021 opens with focus on impact of COVID-19 on global liver disease New data demonstrates that chronic liver disease increased the odds of COVID-19 death by 80% and Pfizer-BioNTech COVID-19 vaccine confers low immunity on people with advanced liver disease …
About EASL and the A-TANGO Consortium The A-TANGO Consortium, a five-year project, consists of 14 institutions across eight countries in Europe. It aims to perform Phase II clinical studies of an innovative therapeutic strategy that targets inflammation and improves liver regeneration – a novel c…
EASL honours Rare Disease Day, taking place this Sunday, 28 February. An estimated 300 million people globally are affected by rare diseases – diseases of which 6,000 have been identified. The day serves to raise awareness among the general public and decision-makers about rare diseases and their…
9 February 2021 By end-January 2021, COVID-19, the systemic disease caused by the pandemic spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), accounted for 2.2 million deaths worldwide and for 100 million individuals infected, according to estimates from the World Health Orga…
Digital Liver Cancer Summit 2021: New follow-up data from a landmark study of liver cancer patients treated with a combination of atezolizumab and bevacizumab has shown the longest ever survival time in a frontline phase 3 trial of systemic therapy in advanced HCC demonstrating a “major breakthro…
Digital Liver Cancer Summit 2021: A global survey assessing the impact of COVID-19 on liver cancer has revealed delays in the screening, diagnosis, and treatment of the disease, with experts issuing stark warnings on liver cancer survival rates. February 5, 2021 The delays of screening programme…
4 February 2021 The month of February brings together several key actions to tackle cancer globally, and EASL is focussing particularly on the global threat of liver cancer. EASL draws on all these initiatives, in alignment with its goals embedded in our policy and public health strategies. [vc_s…
